Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma

Published:2022-03 Issue:2 Volume:2 Page:100090
ISSN:2667-0267
Container-title:JID Innovations
language:en
Short-container-title:JID Innovations

Author:

Hanly Ailish^ORCID,Gibson Frederick^ORCID,Nocco Sarah^ORCID,Rogers Samantha^ORCID,Wu Muzhou^ORCID,Alani Rhoda M.^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference85 articles.

1. The slow cyclinG phenotype: a growing problem for treatment resistance in melanoma;Ahn;Mol Cancer Ther,2017

2. Phenotype plasticity as enabler of melanoma progression and therapy resistance;Arozarena;Nat Rev Cancer,2019

3. Epigenetic protein families: a new frontier for drug discovery;Arrowsmith;Nat Rev Drug Discov,2012

4. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast;Bachmann;J Clin Oncol,2006

5. A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity;Bajpe;Oncogene,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chitosan/dextran-based organohydrogel delivers EZH2 inhibitor to epigenetically reprogram chemo/immuno-resistance in unresectable metastatic melanoma;Carbohydrate Polymers;2024-12

2. Innovative strategies to study epigenetic regulation and advance precision medicine;Comprehensive Precision Medicine;2024

3. HDAC9/p300/F-actin immunoexpression and migration analysis for malignant melanoma stem cell;Pathology - Research and Practice;2023-10

4. Reversing vemurafenib‐resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects;International Journal of Cancer;2023-06-09

5. Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises;Pharmacology & Therapeutics;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3